Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials

European urology oncology - Tập 3 - Trang 540-543 - 2020
Guru P. Sonpavde1, Gregory R. Pond2, Karim Fizazi3, Johann S. de Bono4, Ethan M. Basch5, Howard I. Scher6, Matthew R. Smith7
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2McMaster University, Hamilton, ON, Canada
3Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France
4Institute of Cancer Research and The Royal Marsden Hospital, London, UK
5University of North Carolina, Chapel Hill, NC, USA
6Memorial Sloan-Kettering Cancer Center, New York, NY, USA
7Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

European urology oncology

Tập 3

540-543

Thông tin tác giả